Edwards Lifesciences revenue and financials

EW · NYSE · USD

$87.23+2.44%+$2.08

Close · October 5, 2026

In the fiscal year ended December 2025, Edwards Lifesciences reported revenue of $6.07B (+11.55% year over year). Net income was $1.07B, a net margin of 17.7%.

Annual revenue · 2025: $6.07B

$2.96B2016
$3.44B2017
$3.72B2018
$4.35B2019
$4.39B2020
$5.23B2021
$4.46B2022
$5.01B2023
$5.44B2024
$6.07B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth: +11.55%; 2025 vs 2024
Net income growth: −74.28%; 2025 vs 2024
Net margin: 17.7%; 2024: 76.7%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Annual
Item	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Total revenue	6,068	5,440	5,010	4,464	5,233	4,386	4,348	3,723	3,435	2,964
Cost of revenue	1,334	1,118	978	724	1,249	1,081	1,114	939	875	797
Gross profit	4,733	4,322	4,032	3,740	3,984	3,306	3,234	2,783	2,560	2,166
Selling, general and administrative	2,084	1,789	1,581	1,357	1,494	—	—	—	—	—
Research and development	1,079	1,053	963	844	903	761	753	622	553	442
Operating income	1,264	1,379	1,309	1,498	1,690	898	1,147	748	1,089	751
EBIT	1,638	1,481	1,487	1,542	1,587	—	—	—	—	—
EBITDA	1,795	1,624	1,609	1,681	1,721	—	—	—	—	—
Interest expense	20.4	19.8	17.6	19.2	18.4	15.8	20.7	29.9	23.2	19.2
Pre-tax income	1,273	1,548	1,372	1,520	1,702	—	—	—	—	—
Income tax	217	152	152	196	199	93.3	120	39.2	451	168
Net income	1,074	4,175	1,402	1,522	1,503	—	—	—	—	—
Net income to common shareholders	1,074	4,175	1,402	1,522	1,503	—	—	—	—	—
Basic EPS	1.84	6.98	2.31	2.46	2.41	1.32	1.68	1.15	2.77	2.67
Diluted EPS	1.83	6.97	2.30	2.44	2.38	1.30	1.64	1.13	2.70	2.61
Average shares (basic)	585	598	607	619	623	—	—	—	—	—
Average shares (diluted)	586	599	609	624	631	632	637	641	216	218